Teva Pharmaceuticals is trading 4.1% up at $9,980 after releasing second-quarter 2026 financial results and holding a conference call on July 29, 2026.
- The company's Q2 earnings report is the primary driver for the stock's performance today, with no other company-specific catalysts identified.
- The move is supported by a broader rally in the healthcare sector, which is currently up 2.56%.